Schrodinger(US:SDGR)2026-02-25 22:30Financial Data and Key Metrics Changes - Schrödinger reported a total revenue of $256 million for 2025, reflecting a 23% growth compared to the previous year [12] - The software business generated approximately $199.5 million in revenue, with an annual contract value (ACV) of $198.5 million, showing strong growth from commercial customers [12][9] - Drug discovery revenue more than doubled to $56.4 million, indicating successful execution across collaborative programs [12][13] - The net loss for the year was $103 million, an improvement from a net loss of $187 million in 2024 [15] Business Line Data and Key Metrics Changes - Software revenue increased by 11%, while drug discovery revenue saw significant growth, more than doubling compared to the prior year [12][13] - The software gross margin decreased to 74% from 80% in 2024, attributed to higher costs associated with contribution revenue from grants [13] - Total operating expenses were $310 million, a decrease of approximately 9% compared to 2024, reflecting cost reduction initiatives [13][14] Market Data and Key Metrics Changes - The company experienced a challenging backdrop of tight pharma budgets and difficult biotech capital markets, yet managed to achieve balanced growth [12] - The materials science business grew from $15 million to $17 million as new capabilities were introduced [20] - The company is targeting additional budgets within existing customers and unlocking opportunities in large markets such as biologics and toxicology [11] Company Strategy and Development Direction - Schrödinger aims to achieve 10%-15% software ACV growth and maintain expense discipline while transitioning to a primarily hosted model [10][26] - The company plans to complete phase 1 studies for SGR-1505 and SGR-3515 and advance collaborative programs [10] - The strategic pivot initiated last year is expected to position the company for long-term success, with a target of achieving positive adjusted EBITDA by the end of 2028 [36][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strategic direction and the potential for growth driven by new product launches, including the predictive toxicology platform [10][41] - The company views the adoption of AI as a tailwind, increasing demand for its software and enhancing its competitive position [56] - Management acknowledged the challenges in the biotech sector but anticipates a recovery over the next three years [72] Other Important Information - The company is transitioning to hosted contracts, which will result in more predictable revenue but may compress gross margins and adjusted EBITDA in the near term [24][66] - Schrödinger's platform is uniquely positioned to leverage AI in drug and materials discovery, with a focus on physics-based simulations [11][8] Q&A Session Summary Question: Impact of transitioning to hosted contracts on profitability - Management confirmed that the transition to hosted contracts is an ongoing process and remains a critical component of the business strategy [39][40] Question: Growth expectations from new products like Predictive Tox - Management indicated that new products, including Predictive Tox, are expected to contribute to growth, with positive feedback from beta testing [41][42] Question: Customer engagement with the transition to hosted platforms - Management noted that customers are increasingly preferring hosted deployments, which allow for faster deployment and enhanced support [51][52] Question: Assumptions regarding biotech recovery and capital allocation - Management expects a normalization of growth in the biotech sector over the next three years and prefers to invest cash into growth opportunities rather than share buybacks [72][71] Question: Clarification on ACV definition and its impact on revenue - Management explained that ACV reflects the value of contracts, while revenue recognition varies based on contract type, with hosted contracts resulting in more predictable revenue [76][78]